The Non-Hodgkin Lymphoma (NHL) Diagnostics Market is witnessing a transformative era, driven by the convergence of high-resolution imaging, molecular profiling, and artificial intelligence. As of 2025, the industry is transitioning from generalized screening to precision diagnostics, allowing clinicians to identify specific NHL subtypes with unprecedented accuracy. This evolution...